Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanasios D Anastasilakis

Showing results (61-70 of 156) with videos related to

Pageof 16
Sort By:
Maturitas|April 9, 2021
Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerationsStergios A Polyzos, Athanasios D Anastasilakis, Zoe A Efstathiadou, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2014
The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrheaJoo-Pin Foo, Stergios A Polyzos, Athanasios D Anastasilakis, et al.
Journal of Clinical Medicine|September 28, 2023
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of DenosumabAthanasios D Anastasilakis, Polyzois Makras, Julien Paccou, et al.
Journal of Clinical Medicine|January 7, 2021
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative ReviewAthanasios D Anastasilakis, Polyzois Makras, Maria P Yavropoulou, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|June 10, 2010
A case report of subacute thyroiditis during pregnancy: difficulties in differential diagnosis and changes in cytokine levelsAthanasios D Anastasilakis, Vassiliki Karanicola, Anargyros Kourtis, et al.
Bone|June 14, 2020
The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosisPolyzois Makras, Socrates E Papapoulos, Stergios A Polyzos, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|February 5, 2021
Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab DiscontinuationAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 28, 2017
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional CasesAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 22, 2019
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical TrialAthanasios D Anastasilakis, Socrates E Papapoulos, Stergios A Polyzos, et al.
Clinical Endocrinology|October 17, 2009
The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosisAthanasios D Anastasilakis, Stergios A Polyzos, Avraam Avramidis, et al.
Pageof 16

Showing results (61-70 of 156) with videos related to

Sort By:
Pageof 16
Maturitas|April 9, 2021
Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerationsStergios A Polyzos, Athanasios D Anastasilakis, Zoe A Efstathiadou, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2014
The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrheaJoo-Pin Foo, Stergios A Polyzos, Athanasios D Anastasilakis, et al.
Journal of Clinical Medicine|September 28, 2023
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of DenosumabAthanasios D Anastasilakis, Polyzois Makras, Julien Paccou, et al.
Journal of Clinical Medicine|January 7, 2021
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative ReviewAthanasios D Anastasilakis, Polyzois Makras, Maria P Yavropoulou, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|June 10, 2010
A case report of subacute thyroiditis during pregnancy: difficulties in differential diagnosis and changes in cytokine levelsAthanasios D Anastasilakis, Vassiliki Karanicola, Anargyros Kourtis, et al.
Bone|June 14, 2020
The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosisPolyzois Makras, Socrates E Papapoulos, Stergios A Polyzos, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|February 5, 2021
Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab DiscontinuationAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 28, 2017
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional CasesAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 22, 2019
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical TrialAthanasios D Anastasilakis, Socrates E Papapoulos, Stergios A Polyzos, et al.
Clinical Endocrinology|October 17, 2009
The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosisAthanasios D Anastasilakis, Stergios A Polyzos, Avraam Avramidis, et al.
Pageof 16